Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RNA Therapeutics Market: mRNA and siRNA Modality Diversification Demand, Lipid Nanoparticle and GalNAc Delivery Growth, and Oncology Indication Expansion Adoption to Drive Steady Market Expansion Through 2036

The global RNA Therapeutics Market was valued at USD 17.2 billion in 2025 and is projected to expand at a steady CAGR of 7.9%, reaching approximately USD 36.8 billion by 2036. This growth trajectory is being driven by sustained commercial and clinical diversification across mRNA, siRNA, antisense oligonucleotide, RNA editing, circular RNA, and self-amplifying RNA modalities, growing reliance on lipid nanoparticle and GalNAc-conjugated delivery platforms, and continued expansion into oncology and neurological disease indications beyond the field’s historical infectious disease and rare genetic disease core. The market comprises a broad portfolio of commercially approved RNA-based vaccines and therapeutics alongside an extensive clinical-stage pipeline spanning emerging modalities including RNA editing and circular RNA technology.

The market’s steady 7.9% CAGR reflects RNA therapeutics’ continued maturation from a narrow COVID-era vaccine and drug distinction into a substantially diversified therapeutic category, generating structured demand from pharmaceutical developers and hospitals well above discretionary specialty pharmaceutical demand growth. The RNA therapeutic landscape has expanded well beyond its historical RNAi, antisense, and mRNA vaccine core into RNA editing, self-amplifying RNA, circular RNA, and other emerging modalities, while lipid nanoparticles and GalNAc conjugates continue to represent the major delivery technologies supporting continued RNA therapeutic growth, particularly for extrahepatic applications. Coverage extending across multiple RNA modalities, mechanisms of action, delivery technologies, and therapeutic areas underscores the breadth of clinical and manufacturing infrastructure now supporting this well-established and continuously diversifying category.

Executive Snapshot

How does mRNA and siRNA modality diversification demand drive the RNA therapeutics market?
Pharmaceutical developers continue to advance mRNA therapeutics, siRNA therapeutics, antisense oligonucleotides, and emerging modalities including RNA editing, circular RNA, and self-amplifying RNA, establishing this modality diversification as the primary driver of current market activity. As the RNA therapeutic landscape continues to expand well beyond its historical RNAi, antisense, and mRNA vaccine core, procurement associated with this broader modality base is expected to remain the dominant category through the forecast period.

What role does lipid nanoparticle and GalNAc delivery growth play in market expansion?
Biopharmaceutical developers continue to rely on lipid nanoparticles and GalNAc conjugates as the major delivery technologies supporting RNA therapeutic growth, sustaining structured demand from developers pursuing these established platforms given their critical role as commercial bottlenecks and differentiators, particularly for extrahepatic applications.

How does oncology indication expansion adoption sustain market growth?
Biopharmaceutical developers increasingly extend RNA therapeutic technology into oncology applications, sustaining structured demand from developers pursuing this substantial therapeutic area alongside continued growth in neurological, cardiovascular, and metabolic disease indications beyond the field’s historical infectious disease and rare genetic disease core.

What is driving demand for RNA therapeutics in RNA editing and circular RNA applications?
Developers pursuing RNA editing therapeutics, including ADAR-based and CRISPR/Cas-based approaches, and circular RNA therapeutics continue to extend the RNA therapeutic landscape well beyond conventional RNAi, antisense, and mRNA vaccine technology, generating incremental demand among clinical-stage biopharmaceutical developers pursuing these emerging modalities.

How does extrahepatic delivery technology demand sustain the market?
Biopharmaceutical developers continue to advance polymer-based, liposomal, exosome-based, and antibody/RNA conjugate delivery systems designed to extend RNA therapeutic technology beyond liver-directed applications, sustaining structured demand from developers pursuing these differentiated delivery platforms for extrahepatic tissue targeting.

Which RNA therapeutics market segments are growing fastest?
The fastest-growing segments include RNA editing and circular RNA therapeutic modalities, oncology and neurological therapeutic areas, extrahepatic delivery technology, and self-amplifying RNA platforms as the category continues to diversify beyond its established commercial core.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: RNA Therapeutics Market

  • mRNA therapeutics sustaining the leading share of current commercial market activity: This modality continues to anchor the substantial majority of current RNA therapeutics commercial revenue given established vaccine and expanding therapeutic applications.
  • Lipid nanoparticles and GalNAc conjugates sustaining the dominant delivery technologies across the category: These established platforms continue to represent the major delivery technologies supporting current RNA therapeutic commercial and clinical activity.
  • Infectious diseases and rare genetic diseases sustaining leading therapeutic area applications while oncology expands: These established indications continue to anchor substantial commercial activity as oncology and neurological applications continue to grow.
  • RNA editing and circular RNA modalities sustaining structured demand growth as increasingly important emerging technology classes: These modalities continue to represent the most significant upgrade to the RNA therapeutic landscape beyond its historical core.
  • Gene silencing mechanisms sustaining a leading share of current mechanism of action activity: This mechanism continues to anchor substantial RNA therapeutic development alongside protein replacement, immune activation, and other mechanisms.
  • Approved and commercialized products sustaining a substantial share of overall market activity alongside a large clinical pipeline: This established commercial base continues to distinguish RNA therapeutics from many other emerging biopharmaceutical categories still concentrated in earlier development stages.

Market Segmentation: RNA Therapeutics Market

By Product
  • Vaccines
    • Prophylactic RNA Vaccines
    • Therapeutic RNA Vaccines
  • Therapeutic Drugs
    • RNA Replacement/Expression Therapies
    • Gene-Silencing Therapies
    • RNA Editing Therapies
    • Splicing-Modulating Therapies
    • Other RNA Drugs
By RNA Therapeutic Modality
  • mRNA Therapeutics
  • siRNA Therapeutics
  • Antisense Oligonucleotides (ASOs)
  • miRNA Therapeutics
  • shRNA Therapeutics
  • Antisense RNA/Other RNA Silencing
  • RNA Editing Therapeutics
  • Circular RNA (circRNA) Therapeutics
  • Self-Amplifying RNA (saRNA)
  • Trans-Splicing RNA
  • Aptamer Therapeutics
  • Other RNA Therapeutics
By Mechanism of Action
  • Protein Replacement/Protein Expression
  • Gene Silencing
  • Gene Splicing Modification
  • RNA Editing
  • Immune Activation
  • Immune Modulation
  • Translation Modulation
  • Targeted RNA Delivery
  • Other Mechanisms
By Route of Administration
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Intrathecal
  • Intravitreal
  • Intradermal
  • Intranasal
  • Oral
  • Local/Intratumoral
  • Other Routes
By Delivery Technology
  • Lipid Nanoparticles (LNPs)
  • GalNAc Conjugates
  • Polymer-Based Delivery
  • Liposomal Delivery
  • Viral Vector-Based Delivery
  • Antibody/RNA Conjugates
  • Peptide-Based Delivery
  • Exosome-Based Delivery
  • Naked RNA
  • Other Delivery Systems
By Indication
  • Oncology
  • Rare Genetic Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Respiratory Diseases
  • Ophthalmic Diseases
  • Autoimmune & Inflammatory Diseases
  • Hematological Diseases
  • Other Therapeutic Areas
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Contract Research Organizations
  • Contract Development & Manufacturing Organizations
  • Other End User
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: RNA Therapeutics Market

  1. Sustained modality diversification driving continued RNA therapeutic pipeline development beyond the historical core: Expansion into RNA editing, circular RNA, and self-amplifying RNA continues to support structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing developer reliance on lipid nanoparticle and GalNAc delivery platforms supporting continued commercial expansion: These established technologies continue to attract structured investment given their critical role in RNA therapeutic performance and tissue targeting.
  3. Continued extension into oncology and neurological disease broadening the addressable therapeutic market: This diversification continues to substantially broaden the category’s overall addressable market beyond infectious disease and rare genetic disease.
  4. Sustained investment in extrahepatic delivery technology supporting expanded tissue-targeting capability: Polymer-based, liposomal, and other non-LNP systems continue to attract structured developer investment pursuing broader therapeutic applicability.
  5. Growing manufacturing capacity investment supporting improved RNA therapeutic production scalability: Continued infrastructure investment continues to focus industry attention on addressing persistent manufacturing capacity constraints.
  6. Maturing regulatory pathways supporting continued approval momentum across multiple RNA therapeutic modalities: Accumulating global regulatory experience continues to support faster and more predictable approval pathways for new RNA-based candidates.

Regional Outlook: RNA Therapeutics Market

  • North America: The United States accounts for the largest share of global demand, supported by extensive biopharmaceutical developer activity, substantial manufacturing infrastructure, and the largest concentration of approved RNA therapeutic products globally.
  • Europe: Germany, the United Kingdom, and Switzerland anchor regional demand, supported by growing specialized treatment center capacity and an established regulatory pathway through the European Medicines Agency.
  • Asia-Pacific: China, Japan, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers expand RNA therapeutic manufacturing and clinical development capacity.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized treatment centers begin to expand RNA therapeutic access.

Competitive Landscape: RNA Therapeutics Market

Key Players
Moderna, Inc., Pfizer Inc., BioNTech SE, Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Novartis AG, Arrowhead Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Wave Life Sciences Ltd., GSK plc, Sanofi S.A., AstraZeneca plc, Amgen Inc., Regeneron Pharmaceuticals, Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Beam Therapeutics Inc., Korro Bio, Inc., Orna Therapeutics, Inc., Laronde, Inc.

  • Moderna, Inc. [March 2026] — confirmed continued commercial expansion across its RNA therapeutic portfolio spanning infectious disease, oncology, and rare disease applications, with the company noting sustained investment across more than a dozen distinct disease programs.
  • Alnylam Pharmaceuticals, Inc. [December 2025] — reported continued commercial growth across its GalNAc-conjugated siRNA portfolio, with the company noting sustained demand across multiple approved indications.
  • Ionis Pharmaceuticals, Inc. [September 2025] — confirmed continued clinical development across its antisense oligonucleotide pipeline, with the company reporting structured interest in extending RNA therapeutic technology to additional neurological and cardiovascular indications.

Consultant POV

The RNA Therapeutics Market’s steady 7.9% CAGR from USD 17.2 billion in 2025 toward approximately USD 36.8 billion by 2036 is anchored in sustained mRNA and siRNA modality diversification demand, growing lipid nanoparticle and GalNAc delivery activity, and continued oncology indication expansion adoption. Sustained clinical and manufacturing investment from companies including Moderna, Inc., Alnylam Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. confirms the RNA Therapeutics Market will sustain steady growth through 2036.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report